Segall Bryant & Hamill’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-27,800
| Closed | -$7.47M | – | 310 |
|
|
2023
Q3 | $7.47M | Sell |
27,800
-245
| -0.9% | -$61.1K | 0.09% | 259 |
|
|
2023
Q2 | $6.23M | Sell |
28,045
-664
| -2% | -$154K | 0.07% | 306 |
|
|
2023
Q1 | $6.94M | Buy |
28,709
+140
| +0.5% | +$34.4K | 0.07% | 288 |
|
|
2022
Q4 | $7.5M | Buy |
28,569
+634
| +2% | +$170K | 0.08% | 262 |
|
|
2022
Q3 | $6.3M | Buy |
27,935
+117
| +0.4% | +$28.4K | 0.08% | 272 |
|
|
2022
Q2 | $6.76M | Sell |
27,818
-531
| -2% | -$130K | 0.08% | 265 |
|
|
2022
Q1 | $6.85M | Sell |
28,349
-2,007
| -7% | -$461K | 0.07% | 264 |
|
|
2021
Q4 | $6.81M | Sell |
30,356
-4,578
| -13% | -$966K | 0.06% | 263 |
|
|
2021
Q3 | $7.43M | Buy |
34,934
+8,269
| +31% | +$1.9M | 0.07% | 254 |
|
|
2021
Q2 | $6.5M | Sell |
26,665
-13,562
| -34% | -$3.34M | 0.06% | 278 |
|
|
2021
Q1 | $9.99M | Sell |
40,227
-18,917
| -32% | -$4.51M | 0.1% | 217 |
|
|
2020
Q4 | $13.6M | Sell |
59,144
-5,694
| -9% | -$1.31M | 0.15% | 162 |
|
|
2020
Q3 | $16.5M | Sell |
64,838
-1,537
| -2% | -$381K | 0.22% | 109 |
|
|
2020
Q2 | $15.7M | Sell |
66,375
-5,731
| -8% | -$1.31M | 0.26% | 95 |
|
|
2020
Q1 | $14.6M | Sell |
72,106
-7,451
| -9% | -$1.63M | 0.3% | 84 |
|
|
2019
Q4 | $19.1M | Sell |
79,557
-4,352
| -5% | -$959K | 0.3% | 85 |
|
|
2019
Q3 | $16.3M | Sell |
83,909
-3,512
| -4% | -$674K | 0.25% | 102 |
|
|
2019
Q2 | $16.1M | Buy |
87,421
+597
| +0.7% | +$107K | 0.24% | 112 |
|
|
2019
Q1 | $16.5M | Sell |
86,824
-2,097
| -2% | -$400K | 0.26% | 110 |
|
|
2018
Q4 | $17.3M | Sell |
88,921
-1,983
| -2% | -$387K | 0.3% | 93 |
|
|
2018
Q3 | $18.8M | Sell |
90,904
-4,584
| -5% | -$903K | 0.28% | 94 |
|
|
2018
Q2 | $17.6M | Buy |
95,488
+86,599
| +974% | +$15.3M | 0.27% | 104 |
|
|
2018
Q1 | $1.51M | Sell |
8,889
-146
| -2% | -$26.8K | 0.04% | 320 |
|
|
2017
Q4 | $1.57M | Buy |
9,035
+27
| +0.3% | +$4.78K | 0.03% | 308 |
|
|
2017
Q3 | $1.68M | Buy |
9,008
+885
| +11% | +$157K | 0.04% | 313 |
|
|
2017
Q2 | $1.4M | Buy |
8,123
+260
| +3% | +$42.3K | 0.03% | 335 |
|
|
2017
Q1 | $1.29M | Sell |
7,863
-107
| -1% | -$17.8K | 0.03% | 332 |
|
|
2016
Q4 | $1.17M | Buy |
7,970
+195
| +3% | +$29.3K | 0.03% | 336 |
|
|
2016
Q3 | $1.3M | Buy |
7,775
+305
| +4% | +$51.6K | 0.03% | 327 |
|
|
2016
Q2 | $1.14M | Hold |
7,470
| – | – | 0.03% | 345 |
|
|
2016
Q1 | $1.12M | Sell |
7,470
-250
| -3% | -$37.1K | 0.03% | 344 |
|
|
2015
Q4 | $1.25M | Buy |
7,720
+300
| +4% | +$47.2K | 0.03% | 325 |
|
|
2015
Q3 | $1.03M | Hold |
7,420
| – | – | 0.03% | 347 |
|
|
2015
Q2 | $1.14M | Hold |
7,420
| – | – | 0.03% | 340 |
|
|
2015
Q1 | $1.19M | Buy |
7,420
+600
| +9% | +$94.5K | 0.03% | 330 |
|
|
2014
Q4 | $1.09M | Buy |
6,820
+100
| +1% | +$15.6K | 0.02% | 342 |
|
|
2014
Q3 | $944K | Sell |
6,720
-67
| -1% | -$8.75K | 0.02% | 357 |
|
|
2014
Q2 | $803K | Sell |
6,787
-952
| -12% | -$110K | 0.02% | 357 |
|
|
2014
Q1 | $955K | Sell |
7,739
-1,601
| -17% | -$194K | 0.02% | 338 |
|
|
2013
Q4 | $1.07M | Buy |
9,340
+100
| +1% | +$11.4K | 0.02% | 329 |
|
|
2013
Q3 | $1.03M | Buy |
9,240
+1,975
| +27% | +$214K | 0.03% | 325 |
|
|
2013
Q2 | $717K | Buy |
+7,265
| New | +$754K | 0.02% | 338 |
|
Other funds holding AMGN
Segall Bryant & Hamill's AMGN Position: Q4 2023 in Review
Segall Bryant & Hamill sold out of Amgen (AMGN) in Q4 2023, closing a stake of 27,800 shares — an estimated $7.47M sold.
Segall Bryant & Hamill first reported a position in AMGN in Q2 2013 and held it in 42 quarters. The position peaked at $19.1M in Q4 2019. 2,714 funds tracked by Wall St. Rank hold AMGN as of Q4 2023.
- Segall Bryant & Hamill reported no remaining Amgen position as of Q4 2023 after selling out during the quarter.
- Segall Bryant & Hamill sold 27,800 Amgen shares in Q4 2023, an estimated $7.47M.
- Segall Bryant & Hamill first reported a position in Amgen in Q2 2013 and held it in 42 quarters.
- Segall Bryant & Hamill's Amgen position peaked at $19.1M in Q4 2019.
- 2,714 funds tracked by Wall St. Rank held Amgen as of Q4 2023.
Based on Segall Bryant & Hamill's 13F filing for Q4 2023, filed 14 Feb 2024.